Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy

Autor: Miguel-Angel Berciano-Guerrero, Rocío Lavado-Valenzuela, Aurelio Moya, Luis delaCruz-Merino, Fátima Toscano, Javier Valdivia, Victoria Castellón, Fernando Henao-Carrasco, Pilar Sancho, Juan-Luis Onieva-Zafra, Ismael Navas-Delgado, Antonio Rueda-Dominguez, Elisabeth Perez-Ruiz, Emilio Alba
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Biomedicines, Vol 10, Iss 2, p 284 (2022)
Druh dokumentu: article
ISSN: 10020284
2227-9059
DOI: 10.3390/biomedicines10020284
Popis: Targeted therapy in metastatic melanoma often achieves a major tumour regression response and significant long-term survival via the release of antigens that reinduce immunocompetence. The biomarkers thus activated may guide the prediction of response, but this association and its mechanism have yet to be established. Blood samples were collected from nineteen consecutive patients with metastatic melanoma before, during, and after treatment with targeted therapy. Differential gene expression analysis was performed, which identified the genes involved in the treatment, both in the first evaluation of response and during progression. Although clinical characteristics of the patients were poorer than those obtained in pivotal studies, radiological responses were similar to those reported previously (objective response rate: 73.7%). In the first tumour assessment, the expression of some genes increased (CXCL-10, SERPING1, PDL1, and PDL2), while that of others decreased (ARG1, IL18R1, IL18RAP, IL1R1, ILR2, FLT3, SLC11A1, CD163, and S100A12). The analysis of gene expression in blood shows that some are activated and others inhibited by targeted therapy. This response pattern may provide biomarkers of the immune reinduction response, which could be used to study potential combination treatments. Nevertheless, further studies are needed to validate these results.
Databáze: Directory of Open Access Journals